Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma

The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Zachary A., Frederick, Dennie T., Ahmed, Zain, Wargo, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913/
https://www.ncbi.nlm.nih.gov/pubmed/23762807
http://dx.doi.org/10.4161/onci.24320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667913/
https://www.ncbi.nlm.nih.gov/pubmed/23762807
http://dx.doi.org/10.4161/onci.24320

Ejemplares similares